Global Public Affairs Head, Alpha-antitrypsin deficiency; AATD and Cross Rare Diagnostic Ini

Job Title:

Global Public Affairs Head, Alpha-1 antitrypsin deficiency (AATD) and Cross Rare Diagnostic Initiatives

Location:

Cambridge, MA / Morristown, NJ / Washington, DC

Join the team transforming care for people with immune challenges, rare diseases, cancers, and neurological conditions. In Specialty Care, you’ll help deliver breakthrough treatments that bring hope to patients with some of the highest unmet needs.

Sanofi (NYSE: SNY) is a leading global integrated healthcare company that discovers, develops and distributes therapeutic solutions to improve the lives of everyone. With 100,000 dedicated professionals in more than 100 countries, Sanofi is devoted to advancing healthcare around the world. Sanofi is structured in 4 Global Business Units (GBUs):
Specialty Care, General Medicine, Vaccines, and Consumer Healthcare.

Global Public Affairs (PA) is an essential partner in the successful execution of the company’s strategy. Our purpose is to create the conditions that promote scientific innovation and enable sustainable access to Sanofi Specialty Care portfolio. We do this by engaging with patients, scientific associations, policy makers and other relevant stakeholders to shape the policy environment for specialty care and create the sustainable conditions for access to innovation.

Our ambition is to be a forward leaning, industry leading and trailblazing Global PA organization that is actively shaping the future health landscape, changing the conversation on the value of innovation and building bridges. The Global PA team for Sanofi Specialty Care is organized by Therapeutic Areas (TA) and provides support to each TA across geographies.

Company-paid relocation benefits will be offered for this position.

The Global Public Affairs Head, Alpha-1 antitrypsin deficiency (AATD) and Cross Rare Diagnostic Initiatives serves as a PA expert to the Rare Diseases (RD) franchise. He/ She works closely with the Global brand teams (GBT) and Global Project Team (GPT) in developing global public affairs strategies to meet key business objectives. He/ She collaborates with the Local PA teams to ensure relevance of global strategy, alignment on resource prioritization, and consistency in execution.

The candidate also work closely with cross-functional partners to advance rare diagnostic initiatives, and serve as deputy to the Head of Global Public Affairs Rare Diseases.

We’re an R&D-driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. Our deep understanding of the immune system – and innovative pipeline – enables us to invent medicines and vaccines that treat and protect millions of people around the world. Together, we chase the miracles of science to improve people’s lives.

The Global Public Affairs Alpha-1 antitrypsin deficiency (AATD) and rare diagnostic initiatives is responsible for developing and executing global public affairs plans to deliver on the strategic objectives of the franchise, with a focus on AATD/Efdoralprin Alfa and cross rare diagnostic initiatives. This role will also serve as a deputy to the Head of Global Public Affairs for Rare Diseases, leading transversal activities to support the team’s functioning and impact.

• Drive implementation of a robust Global PA strategy to achieve the vision for the franchise in prioritized markets, establishing the company’s commitment to the alpha-1 patient community, supporting high priority business objectives, and preparing the environment (market shaping) for the launch and uptake of Efdoralprin alfa.
• Through scientific exchanges, evidence generation, community engagement, advocacy development, policy‑shaping, and other high impact public affairs initiatives, address unmet needs across the patient journey, including patient access to treatment, and elevate care goals.
• Manage strong relationships with patient groups (e.g., Alpha‑1 Foundation, Alpha‑1 Europe Alliance) and key stakeholders to ensure that the “voice of the patient” is central in shaping business strategy.
• Ensure external community input is considered/incorporated into programs…